

ICH E21: inclusion of pregnant & breastfeeding individuals in clinical trials

Presented by Corinne de Vries on 20 September 2023 Head of Translational Sciences, Department of Scientific Evidence Generation Human Medicines Division





Presentation outline

- EMA strategic approach to reducing the information gap of medicine B/R in pregnancy & breastfeeding
- Addressing the information gap: what's in scope for ICH E21



Pregnancy & breastfeeding considerations in EU marketing authorisations: reality of medicine use in pregnancy


130 million births globally per annum, 5 million in Europe

In high resource countries:

90% of pregnant women take medications in pregnancy

- 25% chronic diseases
- Infections
- Complications of pregnancy
- Unplanned pregnancies


Similar disorders, plus 10% postnatal depression, in breastfeeding Labelling information on pregnancy & breastfeeding generally uninformative



696.271 live births in UK and Wales (2016)



Pregnancy strategy: opportunities throughout product life cycle



3 EMA strategy on medicines in pregnancy & breastfeeding



Addressing the information gap

ICH E21: including pregnant & breastfeeding individuals in clinical trials

- Scientific & regulatory principles to ensure appropriate inclusion
- Considerations regarding data collection on dosing, clinical efficacy & safety
 - Trial design
 - Timing of inclusion
 - Strategies for generating data
 - Impact of the treatment modality
- Bridging principles to other ICH guidelines e.g. S5, M3, E11
- Strategies for timing of preclinical testing
- Considerations for the use of prior knowledge to inform assumptions for foetal exposure and metabolism



Consensus Building – Technical Document content

- Clinical Development Plan
 - From 'exclude unless' to 'include unless'; opportunities for lactation / breastfeeding studies; does this fit with timing of reprotox studies
- Study Design & Outcomes
 - RCT vs open label, design implications when retaining vs recruiting, what exposure measures & outcome measures, implications of the fact pregnancy lasts 9 months
- Recruitment and Retention Strategies
 - If & when to change to open label arm, unblinding or not
- Ethical, Regulatory and Legal considerations (high level)



Work plan: Key Milestones

Expected Completion date	Deliverable
Jul 2023	Submited updated Work Plan
Jun – Dec 2023	Continue drafting Technical Document (Step 1)
Oct/Nov 2023	Face-to-Face meeting to work on the Technical Document
Q1/Q2 2024	Consultation with other WGs
Jun 2024	<i>Face-to-Face meeting to discuss and implement input from the WGs and advance drafting of Technical Document</i>
Q4 2024	PWP review and incorporate feedback
Q1 2025	Step 1 Sign off



Thank you

Further information

corinne.devries@ema.europa.eu

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands **Telephone** +31 (0)88 781 6000 **Send us a question** Go to www.ema.europa.eu/contact

